ClinicalTrials.gov
public full text
Public Domain
Bevacizumab and Sorafenib in Treating Patients With Unresectable Stage III or Stage IV Malignant Melanoma
Conceptio Open Archive
Analyze & explore related research in Conceptio
Connect this record directly into your research workflow or AI agent. Explore citations across open repositories, query full text, and export structured proof bundles.
This document is indexed with metadata only: full text is not available in the archive for this record. Open the official source ↗
Related documents
- A Randomized, Controlled, Multi-center, Phase III Clinical Study to Investigate Recombinant Humanized PD-1 Monoclonal Antibody Injection (JS001) Versus Dacarbazine as the 1st-line Therapy for Unresectable or Metastatic Melanoma#1096290
- Study of Dabrafenib, Trametinib and Metformin for Melanoma Patients#405114
- Treatment Study Using Bevacizumab for Patients With Adrenocortical Carcinoma#1044792
- Insurance, race, and socioeconomic disparities in systemic therapy receipt for melanoma in the United States: a systematic review#4625
- S0420, Sorafenib in Treating Patients With Recurrent or Metastatic Head and Neck Cancer#857723
Record · ID 208468
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Retrieved via Conceptio: every document is proof-bundled with source, license, and retrieval metadata.
Bring this data into your agent: Connect via MCP or API · 20 free credits to start · no card required
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive
Read the Docs → · View CLI source on GitHub · Conceptio Open Knowledge Archive